BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Certara Corporation Removes All Uncertainty Regarding Proposal to Acquire Symyx Technologies, Inc. (SMMX)


6/23/2010 11:40:31 AM

June 23, 2010 is included below:

June 23, 2010

To the Board of Directors of Symyx Technologies, Inc.

Gentlemen,

We reviewed your description of our most recent proposal and your reasons for rejecting it reflected in your disclosures to your stockholders on June 21, 2010. Our June 17 proposal was carefully crafted to provide assurance to you regarding certainty of closure and to provide superior value to Symyx stockholders. While we respectfully disagree with your comments regarding value, we regret that we left any room for concern regarding certainty of closure.

In the interest of erasing any such concern, I am happy to transmit to you today a revised proposal that should remove any doubt in the minds of you or the Symyx stockholders that our proposal provides certainty of closure. Specifically:

  • Our offer to enter into the enclosed merger agreement is irrevocable, effective immediately.
  • Provided you recommend that Symyx stockholders vote AGAINST the Accelrys merger, your ability to accept our offer will be effective for 24 hours beginning on the earlier of:
    • Accelrys' termination of the Accelrys merger agreement due to your recommendation change; and
    • the rejection of the Accelrys merger agreement by the Symyx stockholders at which point you can terminate the agreement.
  • To make this offer binding, we enclose a signed merger agreement and signed guarantee of our obligations in your favor from Vector Capital.

Once the Accelrys merger agreement is terminated as described above, you need only countersign and return the enclosed merger agreement, and we will be under binding contract. By making the offer irrevocable in this manner, we have addressed each of the comments regarding certainty that you made in your disclosures.

Our revised offer represents a substantial premium to the implied value of the Accelrys merger. We believe that the continued trading of Symyx stock at a premium to the implied value of the Accelrys merger clearly demonstrates that your stockholders prefer our all-cash deal. Furthermore, as noted in my June 17 letter and evidenced by the enclosed agreement, our offer is not subject to any financing condition and we stand ready to deliver the superior cash value to your stockholders.

By contrast, the ability of Symyx stockholders to realize value for their shares in the Accelrys transaction is subject to substantial uncertainty. Realization of value by Symyx shareholders in excess of our proposed cash premium under the Accelrys proposal will be dependent upon the combined company's ability to successfully navigate the complex tasks involved in operational integration while at the same time attempting to execute on the company's business plan. Any unforeseen adverse developments in the combined company's business or the markets in which it would compete, or any totally unrelated downturn in the financial markets would pose substantial obstacles to realization of value in excess of the price we are offering.

Based on these considerations and the inquiries we have received from Symyx stockholders to date, we are confident that your stockholders will enthusiastically support our revised offer. We urge you, in the exercise of your fiduciary obligations, to endorse our proposal, recommend against the Accelrys transaction and thereby offer your stockholders the opportunity to realize the superior value we stand ready to deliver.

Best regards,


CERTARA CORPORATION


Jim Hopkins

CEO, Authorized Signatory



Contact:

Carol Roos

415-671-7676

croos@brunswickgroup.com



SOURCE Certara



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES